Despite the multiple randomized clinical trials conducted since 2015 that demonstrate improved cardiovascular outcomes with GLP-1 RA use among patients with ASCVD,3,4,5 the rate of use among this subgroup remained low through 2019 (9.4%)—lower than among the overall diabetes cohort (10.7%). This evidence concerns the gene GLP1R and atherosclerosis.